[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587268":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":79,"collaborators":7,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":7,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":7,"enrollmentInfo":91,"targetDuration":7,"studyType":94,"phases":7,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","neoadjuvant immunotherapy","Patients in the cohort received neoadjuvant immune checkpoint inhibitors (ICIs), including PD-1\u002FPD-L1 inhibitors, as part of routine clinical care. The specific regimens included monotherapy or combination with chemotherapy. The agents used may include nivolumab, camrelizumab, sintilimab, atezolizumab, or others.\n\nThis is a retrospective observational study. All interventions (neoadjuvant immunotherapy ± chemotherapy, surgery, or other treatments) were determined by treating physicians as part of standard care. The study aims to evaluate perioperative and survival outcomes across different treatment paths in real-world clinical settings.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Nan Wu, MD","CONTACT","0086-10-88196569","nanwu@bjmu.edu.cn",[20,37,49,64],{"facility":5,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":28,"coordinates":29},"Point",[30,31],116.39723,39.9075,{"lat":31,"lon":30},[34,35],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},{"name":15,"role":36,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"facility":38,"status":21,"city":22,"state":23,"zip":7,"country":25,"countryCode":26,"cosmosGeoPoint":39,"geoPoint":41,"contacts":42},"Peking University Third Hospital",{"type":28,"coordinates":40},[30,31],{"lat":31,"lon":30},[43,47],{"name":44,"role":16,"phone":45,"phoneExt":7,"email":46},"Guangliang Qiang, MD","86-010-82267600","pkudd@bjmu.edu.cn",{"name":44,"role":48,"phone":7,"phoneExt":7,"email":7},"SUB_INVESTIGATOR",{"facility":50,"status":21,"city":51,"state":52,"zip":7,"country":25,"countryCode":26,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Inner Mongolia Hospital of Peking University Cancer Hospital","Hohhot","Inner Mongolia",{"type":28,"coordinates":54},[55,56],111.65222,40.81056,{"lat":56,"lon":55},[59,63],{"name":60,"role":16,"phone":61,"phoneExt":7,"email":62},"Bateer Han, MD","86-13948120033","hanbateer_2004@163.com",{"name":60,"role":48,"phone":7,"phoneExt":7,"email":7},{"facility":65,"status":21,"city":66,"state":67,"zip":7,"country":25,"countryCode":26,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"The Third Affliated Hospital of Kunming Medical University","Kunming","Yunnan",{"type":28,"coordinates":69},[70,71],102.71833,25.03889,{"lat":71,"lon":70},[74,78],{"name":75,"role":16,"phone":76,"phoneExt":7,"email":77},"Yujie Lei, MD","86-0871-68173760","583271025@qq.com",{"name":75,"role":48,"phone":7,"phoneExt":7,"email":7},{"type":36,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Wu Nan","Professor","100587268","safety-efficacy-and-survival-outcomes-of-neoadjuvantinduction-immunotherapy-in-surgical-and-radiotherapeutic-management-of-non-small-cell-lung-cancer-100587268",false,"NCT06926179","Safety, Efficacy, and Survival Outcomes of Neoadjuvant\u002FInduction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer","Safety, Efficacy, and Survival Outcomes of Neoadjuvant\u002FInduction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer: A Multicenter Real-World Study","Inclusion Criteria:\n\n1. Histologically confirmed non-small cell lung cancer (NSCLC), regardless of the presence of EGFR or ALK sensitive driver gene mutations;\n2. Clinical staging of IA-IIIC according to the AJCC 8th Edition before neoadjuvant treatment;\n3. Received at least one cycle of neoadjuvant immunotherapy (with or without chemotherapy);\n4. Assessed as resectable or potentially resectable by surgical experts prior to treatment.\n\nExclusion Criteria:\n\n1. Confirmed M1 disease;\n2. History of previous lung malignancy or other metastatic malignant tumors;\n3. Participation in other randomized controlled trials involving neoadjuvant treatment;\n4. Significant missing clinical data.","ALL","18 Years",{"count":92,"type":93},500,"ESTIMATED","OBSERVATIONAL","This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant\u002Finduction immunotherapy in patients with non-small cell lung cancer (NSCLC). The study covers diverse treatment pathways, including surgery, definitive radiotherapy, and non-surgical strategies. It addresses gaps in existing trials by establishing a comprehensive cohort spanning neoadjuvant\u002Finduction therapy, perioperative management, and follow-up, providing real-world evidence to support treatment decisions in both operable and inoperable cases.",[97,98,99,100],"Lung Cancer (NSCLC)","Neoadjuvant Immunotherapy","Radiotherapy","Lung Surgery",[102,11,103,104,105],"lung cancer","real-world study","radiotherapy","thoracic surgery","2025-04-11",{"date":108,"type":109},"2025-04-16","ACTUAL",{"date":111,"type":109},"2024-12-01",{"date":113,"type":93},"2028-03-31",{"name":5,"class":6},4]